<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00493025</url>
  </required_header>
  <id_info>
    <org_study_id>J0386</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0386</secondary_id>
    <secondary_id>04-02-20-03</secondary_id>
    <secondary_id>ZENECA-IRUSIRES0304</secondary_id>
    <secondary_id>CDR0000549896</secondary_id>
    <nct_id>NCT00493025</nct_id>
  </id_info>
  <brief_title>Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery</brief_title>
  <official_title>Phase II Study in Operable Adenocarcinoma of the Esophagus to Measure Response Rate and Toxicity of Preoperative Combined Modality Paclitaxel (Taxol®, Bristol-Myers Squibb), Cisplatin (Platinol®, Abbott Laboratories), ZD1839 (IRESSA®) and Radiotherapy Followed by Postoperative ZD1839</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed&#xD;
      for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving these&#xD;
      treatments before surgery may make the tumor smaller and reduce the amount of normal tissue&#xD;
      that needs to be removed. Giving gefitinib after surgery may kill any tumor cells that remain&#xD;
      after surgery.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving paclitaxel, cisplatin, gefitinib,&#xD;
      and radiation therapy followed by surgery and gefitinib works in treating patients with&#xD;
      locally advanced cancer of the esophagus or gastroesophageal junction that can be removed by&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the pathologic complete response rate in patients with resectable, locally&#xD;
           advanced adenocarcinoma of the esophagus or gastroesophageal junction treated with&#xD;
           neoadjuvant paclitaxel, cisplatin, gefitinib, and radiotherapy followed by surgery and&#xD;
           adjuvant gefitinib.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
        -  Determine time to disease progression in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the plasma pharmacokinetics of unbound gefitinib in these patients.&#xD;
&#xD;
        -  Conduct exploratory studies to determine if EGFR pathway component expression and&#xD;
           activation correlates with response to therapy and survival of these patients.&#xD;
&#xD;
        -  Determine if treatment with gefitinib alters the EGFR pathway in these patients.&#xD;
&#xD;
      OUTLINE: This is a prospective study.&#xD;
&#xD;
        -  Neoadjuvant therapy: Patients receive oral gefitinib beginning 14 days prior to the&#xD;
           start of chemoradiotherapy and continuing until 7 days prior to surgery (10-12 weeks).&#xD;
           Patients also receive paclitaxel IV over 1 hour and cisplatin IV over 2-3 hours on days&#xD;
           1, 8, 15, 22, and 29. Patients also undergo radiotherapy 5 days a week for 5 weeks.&#xD;
&#xD;
        -  Surgery: Patients undergo surgical resection 4-6 weeks after the completion of&#xD;
           neoadjuvant therapy.&#xD;
&#xD;
        -  Adjuvant therapy: Patients receive gefitinib once a day beginning 2-8 weeks after&#xD;
           surgery and continuing for up to 1 year in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Blood samples are obtained at baseline and periodically during study for pharmacokinetic&#xD;
      studies. Tumor tissue samples are obtained by core biopsy at baseline for biomarker&#xD;
      correlative studies. Samples are analyzed by IHC to measure expression and activation of&#xD;
      EGFR-signaling pathway biomarkers in pretreatment esophageal tumor tissue, including EGFR and&#xD;
      phosphorylated (p)-EGFR, ERK and p-ERK, Akt and p-Akt, p70s6k and p-p70s6k, and p27.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically for at least 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Closed due to early stopping rule-Low accrual&#xD;
  </why_stopped>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response Rate to the Neoadjuvant Regimen</measure>
    <time_frame>5 years</time_frame>
    <description>Study closed due to early stopping rule. Patient data was not analyzed. No additional information is available to report</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as Assessed by NCI CTC v2.0</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of This Regimen</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between EGFR Pathway Component Expression and Activation With Pathologic Complete Response and Survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Cisplatin IV</description>
    <arm_group_label>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
    <description>Gefitinib IV</description>
    <arm_group_label>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy</arm_group_label>
    <other_name>Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Paclitaxel IV</description>
    <arm_group_label>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy</arm_group_label>
    <other_name>Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <description>Postoperative ZD1839</description>
    <arm_group_label>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy</arm_group_label>
    <other_name>Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Radiotherapy</description>
    <arm_group_label>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy</arm_group_label>
    <other_name>Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the esophagus or gastroesophageal junction&#xD;
             meeting the following criteria:&#xD;
&#xD;
               -  Newly diagnosed disease&#xD;
&#xD;
               -  Surgically resectable tumor&#xD;
&#xD;
               -  Primary esophageal tumor &lt; 20 cm below the incisors&#xD;
&#xD;
               -  Tumor extending ≤ 2 cm into the cardia&#xD;
&#xD;
          -  Stage T2-3, N0-1, M0-1a tumor, as determined by imaging studies and biopsy&#xD;
&#xD;
               -  Documentation by endoscopic ultrasound, endoscopy, and CT scan of the chest and&#xD;
                  abdomen required&#xD;
&#xD;
               -  Any lesion suspicious for metastasis must be biopsied&#xD;
&#xD;
               -  M1a disease (i.e., celiac nodal metastasis) is allowed if other eligibility&#xD;
                  criteria are met&#xD;
&#xD;
               -  T4 disease (i.e., involvement of the pleura, pericardium, or diaphragm) allowed&#xD;
                  provided it is considered resectable&#xD;
&#xD;
          -  No CNS metastasis&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Granulocyte count &gt; 1,000/mm³&#xD;
&#xD;
          -  Platelet count &gt; 75,000/mm³&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
          -  No concurrent illness likely to preclude protocol therapy or surgical resection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after&#xD;
             completion of study therapy Exclusion Criteria&#xD;
&#xD;
          -  Known severe hypersensitivity to gefitinib or any of its excipients&#xD;
&#xD;
          -  Evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated&#xD;
             respiratory, cardiac, hepatic, or renal disease)&#xD;
&#xD;
          -  Evidence of other significant clinical disorder or laboratory finding that would&#xD;
             preclude study participation&#xD;
&#xD;
          -  Evidence of clinically active interstitial lung disease&#xD;
&#xD;
          -  Chronic, stable radiographic changes that are asymptomatic are eligible&#xD;
&#xD;
          -  Prior or concurrent malignancy except basal cell or squamous cell skin cancer,&#xD;
             cervical cancer, or any other curatively treated malignancy from which the patient has&#xD;
             been disease-free and has a survival prognosis of &gt; 5 years&#xD;
&#xD;
          -  Preexisting peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  Incomplete healing from prior oncologic or other major surgery&#xD;
&#xD;
          -  Prior chemotherapy, radiotherapy, or surgery for this cancer&#xD;
&#xD;
          -  More than 30 days since prior nonapproved or investigational drugs&#xD;
&#xD;
          -  Concurrent phenytoin, carbamazepine, barbiturates, rifampin, phenobarbital, or&#xD;
             Hypericum perforatum (St. John's wort)&#xD;
&#xD;
          -  Concurrent oral retinoids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arlene A. Forastiere, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.gov/clinicaltrials</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <results_first_submitted>March 6, 2017</results_first_submitted>
  <results_first_submitted_qc>November 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 6, 2018</results_first_posted>
  <last_update_submitted>November 12, 2018</last_update_submitted>
  <last_update_submitted_qc>November 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy</title>
          <description>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
cisplatin: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
gefitinib: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Posto ZD1839&#xD;
paclitaxel: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
gene expression analysis: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
immunohistochemistry staining method: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
laboratory biomarker analysis: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
pharmacological study: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
adjuvant therapy: Combined Modality Paclitaxel, Cisplatin,</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Trial stopped due to early stopping rule</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy</title>
          <description>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
cisplatin: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
gefitinib: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
paclitaxel: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
gene expression analysis: Combined Modality Paclitaxel, Cisplatin, ZD1839 Radiotherapy Followed by Postoperative ZD1839&#xD;
immunohistochemistry staining method: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
laboratory biomarker analysis: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
pharmacological study: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
adjuvant therapy: Combined Modality Paclitaxel, Cisplatin,</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Trial stopped due to early stopping rule, no data analysis completed.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="7.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Complete Response Rate to the Neoadjuvant Regimen</title>
        <description>Study closed due to early stopping rule. Patient data was not analyzed. No additional information is available to report</description>
        <time_frame>5 years</time_frame>
        <population>Study terminated due to early stopping rule. Therefore, data was not collected to assess this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy</title>
            <description>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
cisplatin: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
gefitinib: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
paclitaxel: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
gene expression analysis: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
immunohistochemistry staining method: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
laboratory biomarker analysis: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
pharmacological study: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
adj therapy: Combined Modality Paclitaxel, Cisplatin,</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response Rate to the Neoadjuvant Regimen</title>
          <description>Study closed due to early stopping rule. Patient data was not analyzed. No additional information is available to report</description>
          <population>Study terminated due to early stopping rule. Therefore, data was not collected to assess this outcome measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity as Assessed by NCI CTC v2.0</title>
        <time_frame>5 years</time_frame>
        <population>Study terminated due to early stopping rule. Therefore, data was not collected to assess this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy</title>
            <description>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
cisplatin: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
gefitinib: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Posto ZD1839&#xD;
paclitaxel: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
gene expression analysis: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
immunohistochemistry staining method: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
laboratory biomarker analysis: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
pharmacological study: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
adjuvant therapy: Combined Modality Paclitaxel, Cisplatin,</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity as Assessed by NCI CTC v2.0</title>
          <population>Study terminated due to early stopping rule. Therefore, data was not collected to assess this outcome measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of This Regimen</title>
        <time_frame>5 years</time_frame>
        <population>Study terminated due to early stopping rule. Therefore, data was not collected to assess this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy</title>
            <description>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
cisplatin: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
gefitinib: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Posto ZD1839&#xD;
paclitaxel: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
gene expression analysis: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
immunohistochemistry staining method: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
laboratory biomarker analysis: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
pharmacological study: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
adjuvant therapy: Combined Modality Paclitaxel, Cisplatin,</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of This Regimen</title>
          <population>Study terminated due to early stopping rule. Therefore, data was not collected to assess this outcome measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <time_frame>5 years</time_frame>
        <population>Study terminated due to early stopping rule. Therefore, data was not collected to assess this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy</title>
            <description>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
cisplatin: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
gefitinib: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Posto ZD1839&#xD;
paclitaxel: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
gene expression analysis: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
immunohistochemistry staining method: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
laboratory biomarker analysis: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
pharmacological study: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
adjuvant therapy: Combined Modality Paclitaxel, Cisplatin,</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <population>Study terminated due to early stopping rule. Therefore, data was not collected to assess this outcome measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival</title>
        <time_frame>5 years</time_frame>
        <population>Study terminated due to early stopping rule. Therefore, data was not collected to assess this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy</title>
            <description>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
cisplatin: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
gefitinib: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Posto ZD1839&#xD;
paclitaxel: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
gene expression analysis: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
immunohistochemistry staining method: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
laboratory biomarker analysis: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
pharmacological study: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
adjuvant therapy: Combined Modality Paclitaxel, Cisplatin,</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <population>Study terminated due to early stopping rule. Therefore, data was not collected to assess this outcome measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between EGFR Pathway Component Expression and Activation With Pathologic Complete Response and Survival</title>
        <time_frame>5 years</time_frame>
        <population>Study terminated due to early stopping rule. Therefore, data was not collected to assess this outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy</title>
            <description>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
cisplatin: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
gefitinib: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Posto ZD1839&#xD;
paclitaxel: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
gene expression analysis: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
immunohistochemistry staining method: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
laboratory biomarker analysis: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
pharmacological study: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
adjuvant therapy: Combined Modality Paclitaxel, Cisplatin,</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between EGFR Pathway Component Expression and Activation With Pathologic Complete Response and Survival</title>
          <population>Study terminated due to early stopping rule. Therefore, data was not collected to assess this outcome measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy</title>
          <description>Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
cisplatin: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
gefitinib: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
paclitaxel: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
gene expression analysis: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
immunohistochemistry staining method: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
laboratory biomarker analysis: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
pharmacological study: Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839&#xD;
adj therapy: Combined Modality Paclitaxel, Cisplatin,</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was closed due to early stopping rule.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Rosalyn Juergens, MD.</name_or_title>
      <organization>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</organization>
      <phone>410-908-7829</phone>
      <email>rjuerge1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

